FDA slams Eli Lil­ly's 'mis­lead­ing' In­sta­gram ad for its type 2 di­a­betes in­jec­tion

In a first for 2022, the FDA’s Of­fice of Pre­scrip­tion Drug Pro­mo­tion has is­sued an un­ti­tled let­ter, which was re­cent­ly sent to Eli Lil­ly over what the agency calls a “mis­lead­ing” and “par­tic­u­lar­ly con­cern­ing” In­sta­gram ad the com­pa­ny post­ed for its type 2 di­a­betes drug Trulic­i­ty.

The ques­tion­able In­sta­gram post, which has since been delet­ed by Lil­ly, failed to ad­e­quate­ly com­mu­ni­cate the in­di­ca­tion and lim­i­ta­tions of use as­so­ci­at­ed with Trulic­i­ty, FDA says.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.